{
    "clinical_study": {
        "@rank": "3001", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "ivacaftor > placebo > ivacaftor > placebo > ivacaftor (open-label period)"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "ivacaftor > placebo > placebo > ivacaftor > ivacaftor (open-label period)"
            }, 
            {
                "arm_group_label": "Sequence 3", 
                "arm_group_type": "Experimental", 
                "description": "placebo > ivacaftor > ivacaftor > placebo > ivacaftor (open-label period)"
            }, 
            {
                "arm_group_label": "Sequence 4", 
                "arm_group_type": "Experimental", 
                "description": "placebo > ivacaftor > placebo > ivacaftor > ivacaftor (open-label period)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a multiple within subject crossover study to evaluate the effect of ivacaftor\n      on lung function in subjects aged 12 years and older with cystic fibrosis (CF) who have\n      phenotypic or molecular evidence of residual CF transmembrane conductance regulator (CFTR)\n      function."
        }, 
        "brief_title": "Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "CFTR Mutations associated with residual CFTR function or defective mRNA splicing include the\n      following:\n\n      R117H, E56K, P67L, D110E, D110H, R117C, R347H, R352Q, A455E, D579G, S945L, L206W, R1070W,\n      F1074L, D1152H, S1235R, D1270N, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A,\n      1811+1.6kbA->G, 711+3A->G, 1898+3A->G, 1898+1G->A, 1717-1G->A, 1717-8G->A, 1342-2A->C,\n      405+3A->C, 1716G/A 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C,\n      621+3A->G, 621+1G->T"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects with confirmed diagnosis of CF\n\n          -  Clinical evidence of residual CFTR function based on any 1 of the following:\n             1)Clinically documented residual exocrine pancreatic function, 2)Sweat chloride value\n             \u226480 mmol/L at screening, or 3) Age of diagnosis \u226512 years and at least 1 copy of a\n             CFTR mutation associated with residual CFTR function or defective mRNA splicing\n\n          -  FEV1 \u226540%\n\n          -  12 years of age or older\n\n          -  Willing to agree to meet the contraception requirements\n\n          -  Able to swallow tablets\n\n        Exclusion Criteria:\n\n          -  A copy of any of the following CFTR mutations: G551D, G178R, S549N, S549R, G551S,\n             G970R, G1244E, S1251N, S1255P, G1349D\n\n          -  Unable to perform spirometry\n\n          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in\n             therapy (including antibiotics) for pulmonary disease within 4 weeks before Day 1\n\n          -  Ongoing participation in another therapeutic clinical study or prior participation in\n             an investigational drug study within the 30 days prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685801", 
            "org_study_id": "VX12-770-113"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "description": "150 mg tablet for oral use, administered every 12 hours", 
                "intervention_name": "ivacaftor", 
                "intervention_type": "Drug", 
                "other_name": "Tradename: KALYDECO"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "description": "tablet for oral use, administered every 12 hours", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Denver", 
                    "country": "United States", 
                    "state": "Colorado"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis, Residual CFTR Function, and FEV1 \u226540% Predicted", 
        "overall_official": {
            "affiliation": "National Jewish Health", 
            "last_name": "Jerry Nick, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Relative change from baseline in percent predicted forced expiratory volume in 1 second (FEV1) after 2 weeks of treatment", 
            "safety_issue": "No", 
            "time_frame": "baseline and 2 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685801"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in lung clearance index (LCI) after 2 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "baseline and 2 weeks of treatment"
            }, 
            {
                "measure": "Relative change from baseline in percent predicted FEV1 after 8 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "baseline and 8 weeks of treatment"
            }, 
            {
                "measure": "Change from baseline in LCI after 8 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "baseline and 8 weeks of treatment"
            }, 
            {
                "measure": "Change from baseline in sweat chloride after 8 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "baseline and 8 weeks of treatment"
            }, 
            {
                "measure": "Change from baseline in weight after 8 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "baseline and 8 weeks of treatment"
            }, 
            {
                "measure": "Safety, as determined by adverse events and vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "baseline through 28 weeks (follow-up visit)"
            }
        ], 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}